Valuation: Sygnis SA

Market Cap 37.04M 9.93M 8.62M 8.04M 7.38M 13.96M 944M 14.11M 94.74M 472M 37.28M 36.46M 1.56B P/E 2024 *
-
P/E 2025 174x
Enterprise Value 39.75M 10.65M 9.25M 8.62M 7.92M 14.98M 1.01B 15.15M 102M 507M 40M 39.13M 1.68B EV / Sales 2024
1.44x
EV / Sales 2025 5.47x
Free-Float
38.48%
Yield 2024 *
-
Yield 2025 -
1 day-0.44%
1 week-2.16%
Current month+1.34%
1 month-12.69%
3 months-24.33%
6 months-44.90%
Current year-47.45%
1 week 1.09
Extreme 1.09
1.15
1 month 1.02
Extreme 1.025
1.4
Current year 1.02
Extreme 1.025
3
1 year 1.02
Extreme 1.025
3.8
3 years 0.28
Extreme 0.28
3.8
5 years 0.28
Extreme 0.28
3.8
10 years 0.18
Extreme 0.176
3.8
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Chief Tech/Sci/R&D Officer - 2018-10-31
Sales & Marketing - 2019-12-31
Director TitleAgeSince
Chairman - -
Chairman - 2025-10-28
Director/Board Member - 2025-10-28
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-2.16%-34.01%-20.91% 9.93M
-0.11%-2.99%0.00%+13.75% 48B
+6.03%+5.22%+420.33%+519.87% 41.13B
-2.21%-6.07%+24.87%+5.20% 37.56B
+2.94%-2.25%+6.15%+59.69% 35.91B
+1.98%+4.74%+12.19%+41.37% 29.86B
+0.47%-3.87% - - 16.12B
+0.31%+0.72%+32.99%+122.25% 16.05B
+0.46%+0.73%+3.81%+17.75% 13.76B
-0.98%-12.98%-4.82%-38.09% 12.1B
Average +0.85%-1.67%+51.28%+80.10% 25.05B
Weighted average by Cap. +1.32%-0.93%+82.47%+116.73%

Financials

2024 2025
Net sales 9.8M 2.63M 2.28M 2.13M 1.95M 3.69M 250M 3.74M 25.07M 125M 9.86M 9.65M 414M 11.33M 3.04M 2.64M 2.46M 2.26M 4.27M 289M 4.32M 28.99M 144M 11.41M 11.16M 479M
Net income -11.29M -3.03M -2.63M -2.45M -2.25M -4.26M -288M -4.3M -28.88M -144M -11.36M -11.12M -477M 404K 108K 94.08K 87.71K 80.58K 152K 10.31M 154K 1.03M 5.15M 407K 398K 17.07M
Net Debt 4.3M 1.15M 1M 932K 857K 1.62M 110M 1.64M 10.99M 54.76M 4.32M 4.23M 181M 2.71M 726K 630K 588K 540K 1.02M 69.07M 1.03M 6.93M 34.53M 2.73M 2.67M 114M
Logo Sygnis SA
Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Employees
-
Date Price Change Volume
26-08-04 PLN 1.135 -0.44% 42,257
26-08-03 PLN 1.140 +1.79% 14,286
26-07-31 PLN 1.120 0.00% 19,369
26-07-30 PLN 1.120 -1.75% 48,264
26-07-29 PLN 1.140 -1.72% 10,069